Quinacrine Trial for Cutaneous Lupus Erythematosus Underway
A clinical trial is currently evaluating the safety and efficacy of quinacrine in treating cutaneous lupus erythematosus (CLE), with a total participation duration of 28 weeks.
Asset / Drug
Drug and asset intelligence for Quinacrine with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.